Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Aug 03, 2026
Cintas Corporation (CTAS): Why the $250 Target Points to +22% Upside Potential

Cintas Corporation (CTAS): Why the $250 Target Points to +22% Upside Potential

Key Takeaways

  • Cintas Corporation (CTAS) currently trades near $205, and the $250 price target represents the highest Wall Street forecast — implying roughly 22% upside from current levels.
  • The strongest bullish case rests on the upcoming UNF (UniFirst) acquisition, which could unlock an estimated $375 million or more in cost and revenue synergies over the coming years.
  • Consistent organic revenue growth of 8–9%, sector-leading return on equity above 40%, and a 42-year streak of dividend increases underscore the company's fundamental durability.
  • Key obstacles include a premium valuation — the stock trades at roughly 37 times forward earnings — and integration risk tied to the UniFirst transaction, which remains pending regulatory approval.
  • The 52-week high near $227 serves as an important near-term resistance level, while the $160–$180 zone has functioned as reliable support during pullbacks.
  • Investors should monitor UniFirst deal closure, quarterly organic growth trends, and whether the stock can decisively break above its prior all-time high before extrapolating toward $250.

Why the $250 Target Matters

The $250 price target has drawn attention because it is the highest on the Street, shared by Wells Fargo and previously aligned with views from Robert W. Baird and Barclays. Wells Fargo analyst Jason Haas reaffirmed an Overweight rating and raised the target to $250 after Cintas reported its fiscal fourth-quarter results in mid-July 2026, highlighting organic growth of 8.4% that beat the 7.3% consensus estimate. At roughly $205 per share, that would equate to a gain of approximately 22%, notable for a company that has delivered strong compounded returns over many years.

Company Overview

Cintas Corporation is a Cincinnati-based provider of business services, primarily known for corporate uniform rental and facility services programs. It serves about one million business customers across North America through two main segments: Uniform Rental and Facility Services, and First Aid and Safety Services. With a market capitalization near $82 billion and trailing twelve-month revenue above $11.2 billion, Cintas holds a leading position in a fragmented industry where scale, route density, and customer retention support lasting advantages.

Key Drivers Behind Potential Growth

The most significant near-term catalyst is the UniFirst acquisition announced in March 2026 at $310 per share in cash and stock, for an enterprise value of about $5.5 billion. The combined company would serve roughly 1.5 million business customers and could benefit from overlapping routes, processing capacity, and supply chains. Baird analyst Andrew Wittmann, who upgraded CTAS to Outperform with a $250 target, suggested the $375 million synergy estimate could turn out conservative. Management expects the transaction to close in the second half of calendar 2026. I also checked this using Tickeron’s AI Screener to compare the stock with peers in the sector.

Separately, Cintas has continued to deliver steady organic growth. Fiscal fourth-quarter revenue came in at $2.91 billion, above the $2.87 billion consensus, while EPS of $1.29 beat estimates by $0.05. Fiscal 2027 EPS guidance of $5.36 to $5.50 reflects confidence in mid-to-high single-digit revenue expansion, aided by pricing power and demand across healthcare, education, hospitality, and government areas.

Valuation Considerations

Cintas has seldom traded at a discount, and current multiples reflect that history. Shares are valued at about 41 times trailing earnings and roughly 37 times forward estimates, with a PEG ratio above 3.0. These levels sit above broader industrials benchmarks, so much of the near-term earnings outlook may already be priced in. Reaching $250 would likely require the market to apply a forward multiple in the low-to-mid 40s on fiscal 2027 or 2028 estimates—possible if the UniFirst integration boosts growth, but challenging if execution falls short.

Potential Risks to Watch

Integration risk around the UniFirst deal is the most immediate concern. Several analysts, including those at Stifel, Goldman Sachs, and Truist Financial, have lowered price targets recently, noting that much of the synergy upside may already be reflected in the price. Truist cut its target from $255 to $225 while keeping a Buy rating, citing ongoing “overhang” until the deal closes. At the more cautious end, Citi maintains a Sell rating with a $160 target, pointing to potential longer-term pressure from remote and hybrid work trends. Insider selling has also increased, with roughly $800,000 in shares sold by corporate insiders in recent months and no offsetting purchases.

Important Technical Levels

From a technical perspective, CTAS trades above both its 50-day moving average near $183 and its 200-day moving average near $184, supporting an intermediate-term uptrend. The 52-week high of $226.75, reached in August 2025, remains key resistance that the stock would need to clear before a sustained move toward $250. On the downside, the $160–$170 area, which aligns with the 52-week low of $161.16 and Citi’s bear-case target, has drawn buyers during past pullbacks and acts as a clear support zone.

Analyst Views and Price Targets

Among the 20 analysts covering Cintas, the consensus is a Moderate Buy with an average 12-month price target near $215, implying about 5% upside from current levels. The range is wide, however—from Citi’s $160 to Wells Fargo’s $250—reflecting differing views on the value the UniFirst deal will ultimately deliver. Following earnings, Bank of America upgraded the stock to Buy with a $230 target, and Goldman Sachs raised its target to $231. These cluster in the $230–$250 area, suggesting many analysts see $250 as reachable if the acquisition executes well.

Final Assessment

The $250 price target for Cintas is ambitious yet supported by identifiable catalysts rather than speculation alone. The UniFirst acquisition offers a concrete earnings-growth driver that could justify a higher valuation multiple if synergies meet or exceed expectations. Steady organic growth, pricing strength, and a resilient business model provide further support. That said, the premium valuation leaves little margin for error, and the spread in analyst targets—from $160 to $250—highlights real uncertainty around execution and demand trends. For $250 to materialize, the market would likely need UniFirst closure without regulatory issues, sustained organic growth above 8% for a couple of quarters, and a market environment that continues favoring high-quality compounders.

Using Tickeron AI Tools for Ongoing Monitoring

In my own analysis, I have found Tickeron’s AI Daily Buy/Sell Signals helpful for tracking shifts in stocks like CTAS. The platform applies AI to evaluate technical patterns and market trends, generating Buy, Sell, or Hold signals that can supplement traditional research and highlight potential changes in sentiment more quickly.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CTAS

CTAS sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for CTAS moved above the 200-day moving average on August 05, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CTAS advanced for three days, in of 349 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 331 cases where CTAS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CTAS moved out of overbought territory on July 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CTAS as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CTAS turned negative on August 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTAS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CTAS broke above its upper Bollinger Band on July 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CTAS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.848) is normal, around the industry mean (7.707). P/E Ratio (41.448) is within average values for comparable stocks, (66.825). CTAS's Projected Growth (PEG Ratio) (3.228) is slightly higher than the industry average of (1.530). Dividend Yield (0.009) settles around the average of (0.020) among similar stocks. P/S Ratio (7.337) is also within normal values, averaging (9.132).

Industry description

The industry produces equipment regularly used in offices by businesses and other organizations, and could range from items like Blank sheet paper, calendars, Label and adhesive paper, paper clips, janitorial supplies, to larger /higher cost products like computers, printers, photocopiers, office furniture and so on. Many businesses in the office supply industry have been expanding into related markets like business cards, plus printing and binding of high quality, high volume business and engineering documents. Some companies in this industry also offer shipping services, including packaging and bulk mailing. Herman Miller, Inc., Steelcase Inc. and HNI Corporation.

Market Cap

The average market capitalization across the Office Equipment/Supplies Industry is 7.73B. The market cap for tickers in the group ranges from 359.74K to 89.97B. MCHSF holds the highest valuation in this group at 89.97B. The lowest valued company is JFIL at 359.74K.

High and low price notable news

The average weekly price growth across all stocks in the Office Equipment/Supplies Industry was -0%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 6%. TISI experienced the highest price growth at 29%, while THH experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Office Equipment/Supplies Industry was 1%. For the same stocks of the Industry, the average monthly volume growth was 27% and the average quarterly volume growth was -36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 57
Price Growth Rating: 55
SMR Rating: 72
Profit Risk Rating: 84
Seasonality Score: -41 (-100 ... +100)
View a ticker or compare two or three
CTAS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of rental and servicing of uniforms and other garments

Industry OfficeEquipmentSupplies

Profile
Details
Industry
Other Consumer Services
Address
6800 Cintas Boulevard
Phone
+1 513 459-1200
Employees
48300
Web
https://www.cintas.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.